An observational study in Inflammatory Bowel Diseases (IBD), Crohns Disease and Ulcerative Colitis (UC), sponsored by University of Glasgow. Active, not recruiting at 8 sites in 6 countries. Open to participants aged 4 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by University of Glasgow · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom — 20 open to participants now, 28 under way, 6 of them phase 3. Inflammatory Bowel Diseases · United Kingdom.
Among the 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom, this one is the 9th largest by planned enrollment of the 42 observational ones that give a count, is one of 10 that started in 2024, is one of 42 observational ones, reaches primary completion later than 12 of the 27 other live ones, and was the 106th registered.
1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.
Browse Inflammatory Bowel Diseases studies →20 of the 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United Kingdom
Ages 18–75
GlaxoSmithKline · Sites in United Kingdom
Ages 18–75
Janssen-Cilag Ltd. · Sites in United Kingdom
Ages 18+
Nutricia UK Ltd · Sites in United Kingdom
Ages 3+
Barts & The London NHS Trust · Sites in United Kingdom
Ages 16+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.
This study: 4 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
112 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 13 · Phase 3 22 · Phase 4 4
First in 2006; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 140 across 626 observational studies indexed under Inflammatory Bowel Diseases.
Median enrollment 95 across the 70 interventional studies, 215 across the 42 observational. Of the 67 that completed or were terminated, 26 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 112 have an industry lead sponsor. The 10 most frequent:
University of Glasgow is the lead sponsor of 145 studies on the registry; 21 are open to participants now.
University of Glasgow has 1 study filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
7 of the studies in Inflammatory Bowel Diseases with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
| NCT06723418University of GlasgowDevelopment and Validation of a New Paediatric Inflammatory Bowel Disease NUTrition Risk Score (PIBD-NUTS) | 2026-12 |
| NCT06956703University of NottinghamNAZA - Nottingham/Astra ZenecA Prospective IBD Cohort Study | 2026-12-31 |
| NCT06877923Nutricia UK LtdElemental 028 Extra Case Studies | 2027-02 |
| NCT06286709University of BirminghamFAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis | 2027-09-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Children with inflammatory bowel disease (IBD) including both Crohn's disease (CD) and ulcerative colitis (UC) can be at high risk of developing malnutrition due to the nature of their condition. It is also believed that some children with IBD, in need of nutritional care, are not identified quickly by their healthcare professionals. This may negatively affect their nutrition, disease progression and general well-being. Hence, it has been proposed that nutritional screening tools or scores (NSTs) should be used to promptly identify children needing further dietetic review and input. Although there are a few NSTs for generic use in sick children at hospital admission, NSTs or scores to use for children with IBD are currently missing. In this study, we would like to test the performance of an existing tool that is routinely used for all sick children at hospital admission (The Paediatric Yorkhill Malnutrition Score or PYMS)(5) and test whether PYMS can detect children with IBD who are at risk of malnutrition. If PYMS doesn't work well, we will develop a specific tool for children with IBD (The Paediatric IBD Nutrition Score or PIBD-NUTS).
All IBD (Crohns disease \& ulcerative colitis) patients (4-18 years) either admitted to hospital, or visiting their gastroenterologist's outpatient clinic for routine visits are eligible.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: Malnutriton Screening Tool (PYMS)
In a pilot implementation study, PYMS will be used on children with IBD attending the outpatient and inpatient hospital clinics
the performance of an existing nutritional screening tool (PYMS) in paediatric IBD patients at different international settings.
The primary outcome measure for our study is to evaluate the performance of an existing nutritional screening tool, the Paediatric Yorkhill Malnutrition Score (PYMS), specifically in pediatric IBD patients across various international settings. We aim to assess its diagnostic accuracy by examining sensitivity and specificity.
Time frame: 1 year
Plan to share: No
Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.